Skip to main content

The rockefeller university

News & HighlightsNews
Displaying 164 of 2907 articles.
How toothless mock viruses could advance research on COVID-19
Scientists have engineered four viruses resembling SARS-CoV-2 to enable faster and safer research on vaccines and treatments.
COVID-19 immunology study reveals universally effective antibodies

New findings characterize human antibody response to SARS-Cov-2, with implications for convalescent plasma therapy, vaccine design, and antibody-based drugs.

How antibodies from llamas may lead to COVID-19 treatment
Llamas make antibodies that are much smaller than their human counterparts, yet still potent. Scientists hope that future drugs based on these molecules could provide new weapons against SARS-CoV-2.
Study reveals first evidence inherited genetics can drive cancer’s spread
Scientists have long struggled to understand what drives a tumor to seed itself elsewhere in the body. New research implicates our own pre-existing genetics.
Rockefeller scientists investigate life-threatening inflammation affecting children with COVID-19
The condition resembles a rare childhood illness, Kawasaki disease. Researchers are analyzing blood samples to find genetic clues to what might be causing it.
The gene hunt to explain why some young, healthy people die from COVID-19
People under 50 without preexisting conditions typically develop mild symptoms of coronavirus infection—but there are exceptions. Researchers are working to identify rare genetic variations that may explain why some in this group have succumbed to the disease.
Scientists are using ‘elite’ antibodies from COVID-19 survivors to develop potent therapies

Most people infected with the coronavirus are able to fight it off because their immune system produces effective antibodies. Rockefeller scientists are working to turn such antibodies into a drug.

Rockefeller scientists launch a broad range of studies into novel coronavirus
Over 130 scientists in 18 labs are conducting research to advance the development of new, urgently needed approaches for the prevention and treatment of COVID-19.
Rockefeller grants commercial license for the development of new HIV drugs
The novel compounds are based on so-called broadly neutralizing antibodies, molecules that make rare people's immune systems capable of fighting HIV. They could potentially yield new treatment and prevention approaches benefitting people around the world, including in developing countries.
Patient with unusually severe infection leads scientists to a rare type of immune deficiency
A rare genetic change may explain why some people die from cytomegalovirus, a stealth pathogen that is often asymptomatic.
View
View